key: cord-0855627-z8758x5u
authors: Le Gars, Mathieu; Sadoff, Jerald; Struyf, Frank; Heerwegh, Dirk; Truyers, Carla; Hendriks, Jenny; Gray, Glenda; Grinsztejn, Beatriz; Goepfert, Paul A.; Schuitemaker, Hanneke; Douoguih, Macaya
title: Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine
date: 2022-04-16
journal: J Infect Dis
DOI: 10.1093/infdis/jiac142
sha: ad6aaf2a8a4c364ba64008be9a9e706c4a7f847a
doc_id: 855627
cord_uid: z8758x5u

This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus type 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited SARS-CoV-2–specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar post-vaccination spike-binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses.

Ad26.COV2.S is a recombinant, replication-incompetent, human adenovirus type 26 (Ad26)-vector-2 based vaccine encoding a prefusion-stabilized SARS-CoV-2 spike (S) protein, shown to be efficacious 3 against COVID-19 disease [1] . 4

The question has arisen whether preexisting immunity against Ad26, the virus from which the non-5 replicating vector in Ad26.COV2.S is derived, may decrease the immunogenicity of its transgene-6 expressed immunogens [2] . Reduced immunogenicity of adenovirus type 5 (Ad5)-vectored transgene-7 expressed immunogens has been reported in individuals who were Ad5-seropositive at baseline [3] . The 8

Ad26 vector from the Janssen Pharmaceuticals AdVac ® platform has been used to develop an approved 9 vaccine against Ebola, a vaccine against COVID-19 disease approved or authorized for emergency use in 10 over 73 countries/regions/territories (as of August 19, 2021), and experimental vaccines against human 11 immunodeficiency virus (HIV) and respiratory syncytial virus that are currently in clinical efficacy trials. 12 Initial findings from clinical trials of Ad26-based vaccines for Ebola, HIV, and COVID-19 do not indicate 13 any impact of preexisting Ad26 neutralizing antibody on immune responses to the transgene-expressed 14 immunogens in these vaccines [4] [5] [6] . Although the proportion of participants with baseline Ad26 15 seropositivity was small in some previous studies [4, 7] , potentially limiting the conclusions about impact 16 on vaccine response, recent Ebola vaccine trials in which the majority of participants had preexisting 17

Ad26 antibodies showed no effect on vaccine-induced immune response [6, 8] . Similarly, there was no 18 impact of Ad26-specific antibody titers on vaccine response in a study of the HIV-1 vaccine that included 19 a high proportion of participants with baseline Ad26-specific neutralizing antibodies [9] . 20

Here, we report an analysis of preexisting anti-Ad26 immunity and post-vaccination SARS-CoV-2 S-21 protein-specific antibody titers elicited by the Ad26.COV2.S vaccine in participants from Brazil, South 22

Africa, and the United States, representing a more geographically and racially diverse population than 1 previously evaluated for Ad26.COV2.S [5]. 2

We conducted a secondary analysis of data from 380 randomly selected participants in the ongoing 4 phase 3 ENSEMBLE trial (ClinicalTrials.gov NCT04505722) from Brazil, South Africa, and the United States 5 [1, 10] . The trial began enrollment on September 21, 2020, and the data-cutoff date for the present 6 analysis was January 22, 2021. The trial was conducted in accordance with the Declaration of Helsinki 7 and International Conference on Harmonization's guidelines on Good Clinical Practice; the protocol and 8 amendments were approved by institutional review boards per local regulations. Written informed 9 consent was obtained from all participants prior to trial enrollment. 10 SARS-CoV-2 S-specific antibodies at baseline (day 1) and 28 days post-vaccination (day 29) were 11 measured using an enzyme-linked immunosorbent assay (S-ELISA). Preexisting anti-vector immunity was 12 assessed pre-vaccination (day 1) in a virus neutralization assay (VNA) for Ad26 [11] . 13

Among the vaccine groups for whom day 29 S-ELISA data were available, 27 of 86 (31%) pre-vaccination 15 sera had neutralizing activity against Ad26 in Brazil, while in South Africa 53 of 80 (66%) sera tested had 16 Seroconversion rates for S antibodies were generally similar when stratified by preexisting anti-Ad26 3 immunity in South Africa (96% vs 92% for baseline-negative vs -positive anti-Ad26 VNA, respectively) 4 and tended to be somewhat lower in baseline-positive participants in Brazil (100% vs 85%) ( Figure 1B) . 5

Only 1 participant in the United States had detectable Ad26 VNA titers at baseline, thus precluding any 6 conclusions for this region. The day 29 S antibody levels for South African participants with preexisting 7 anti-Ad26 immunity were higher than those of the Brazilian participants (GMC: 392 vs 200, respectively) 8 despite 2-fold higher Ad26 VNA titers at baseline in South African participants versus Brazilian 9 participants (geometric mean titer 41 vs 22, respectively; Supplemental Table and Figure) . Although 10 anti-S immunity appeared to be lower in participants with preexisting anti-Ad26 immunity in Brazil when 11 compared with Ad26 baseline-negative participants (with no overlap of the 95% CIs), slightly higher 12 titers were observed in participants with preexisting anti-Ad26 immunity in South Africa compared with 13 baseline Ad26 baseline-negative participants ( Figure 1B) . 14 Across all participants for whom immunogenicity data were available in the 3 countries evaluated, the 15 correlation between preexisting Ad26 VNA titers and post-vaccination S-ELISA titers was low to 16 negligible ( Figure 1C) . 17

These findings, together with data from previous trials, show that prevaccination baseline immunity to 19

Ad26 has no clear impact on humoral immune responses against immunogens expressed from 20 transgenes delivered by Ad26-based vaccines [1, 5] . Robust vaccine efficacy against severe-critical 21 COVID-19 demonstrated in ENSEMBLE was similar across countries where preexisting immunity against 22 the Ad26 vector was observed, especially in South Africa and Brazil, compared to the United States, 23

where very little preexisting anti-Ad26 immunity was detected [1, 10] . Inconsistent trends in anti-S 1 immunity among participants with preexisting Ad26 immunity in South Africa versus Brazil may be 2 explained by the small sample size of these country-specific analyses. Efficacy against symptomatic 3 infection was highest in the United States in the ENSEMBLE study [1, 10] , which could be due to 4 differences in the circulating variants at the time of the study or potential differences in preexisting anti-5

Ad26 immunity in different countries; this question will be evaluated in a correlate of protection 6 analysis. S-ELISA GMCs and responder rates in ENSEMBLE were comparable to those in the previous 7 phase 1/2a study of Ad26.COV2.S [5] . A limitation of this study was that we did not evaluate the impact 8 of preexisting Ad26 immunity on cellular immune responses, which may be an important contributor to 9 protection mediated by Ad26.COV2.S. The results of this study suggest that neutralizing antibodies 10 against Ad26 induced by immunization with Ad26-vectored vaccines will have little effect on subsequent 11 doses of the same vaccine, consistent with the previously reported 3-to 4-fold increased immune 12 responses after a second dose given 2 months after the first dose [5], and a 9-fold increase in spike 13 binding antibodies after a booster dose given 6 months after a single dose [12] . 14 Figure 1 . A, Country-specific humoral immunogenicity was measured by S-ELISA at baseline (day 1) and 2 28 days post-vaccination with Ad26.COV2.S at a dose level of 5×10 10 vp. Response is described using 3

GMCs of SARS-CoV-2 S-protein binding antibodies and percentage of participants with a response (% 4 resp) in Brazil, South Africa, and the United States. Arrows indicate the day of vaccination (Ad26.COV2.S 5 recipients) or placebo injection. B, Response by preexisting anti-Ad26 immunity at day 29 is shown 6 stratified by preexisting anti-Ad26 immunity in Brazil, South Africa, and Brazil and South Africa 7 combined; minimal preexisting immunity was observed in the United States. C, Correlation of 8 preexisting anti-Ad26 antibody titers and post-vaccination S-ELISA response was low to negligible 9 (P>0.05). Abbreviations: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GMC, 10 geometric mean concentration; IC 50 , half maximal inhibitory concentration; LLOQ, lower limit of 11 quantitation; NS, not significant; S-ELISA, enzyme-linked immunosorbent assay to assess SARS-CoV-2 12 spike (S) protein-specific antibodies; ULOQ, upper limit of quantitation; VNA, virus neutralization assay; 13 vp, viral particles. 

Safety and efficacy of single-dose Ad26.COV2.S 2 vaccine against Covid-19

Vaccines based on replication incompetent Ad26 viral 4 vectors: Standardized template with key considerations for a risk/benefit assessment

Immunogenicity and safety of a recombinant adenovirus 7 type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, 8 double-blind, placebo-controlled, phase 2 trial

Safety and immunogenicity of two heterologous HIV 10 vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-11 group, placebo-controlled, double-blind, phase 1/2a study

Interim results of a phase 1-2a trial of Ad26.COV2.S 13 COVID-19 vaccine

Safety and immunogenicity of 2-dose heterologous 15

Ebola vaccination in healthy and HIV-infected adults: A 16 randomised, placebo-controlled Phase II clinical trial in Africa

A double-blind, randomized, placebo-18 controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-zika virus vaccine